RedHill Biopharma (RDHL) Retained Earnings (2011 - 2025)

RedHill Biopharma (RDHL) has reported Retained Earnings for 15 consecutive years, with -$413.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Retained Earnings changed 0.25% year-over-year to -$413.8 million in Q4 2025; TTM through Dec 2025 was -$413.8 million, a 0.25% change from a year earlier, with the FY2025 full-year figure at -$413.8 million, changed 0.25% from the prior year.
• Retained Earnings was -$413.8 million for Q4 2025 at RedHill Biopharma, up from -$418.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$302.3 million in Q1 2021 and troughed at -$433.9 million in Q4 2022.
• A 5-year average of -$387.8 million and a median of -$397.2 million in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings slumped 35.82% in 2021 and gained 6.02% in 2023, its largest moves.
• Over 5 years, Retained Earnings stood at -$367.9 million in 2021, then fell by 17.94% to -$433.9 million in 2022, then climbed by 6.02% to -$407.7 million in 2023, then decreased by 1.73% to -$414.8 million in 2024, then rose by 0.25% to -$413.8 million in 2025.
• The last three Retained Earnings figures came in at -$413.8 million (Q4 2025), -$418.1 million (Q2 2025), and -$414.8 million (Q4 2024), per Business Quant data.